Last reviewed · How we verify

Duobrii® — Competitive Intelligence Brief

Duobrii® (Duobrii®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical corticosteroid and retinoid combination. Area: Dermatology.

marketed Topical corticosteroid and retinoid combination Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Duobrii® (Duobrii®) — Icahn School of Medicine at Mount Sinai. Duobrii is a fixed-dose combination of halobetasol propionate (a potent topical corticosteroid) and tazarotene (a retinoid) that reduces inflammation and normalizes skin cell differentiation in psoriasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Duobrii® TARGET Duobrii® Icahn School of Medicine at Mount Sinai marketed Topical corticosteroid and retinoid combination Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical corticosteroid and retinoid combination class)

  1. Icahn School of Medicine at Mount Sinai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Duobrii® — Competitive Intelligence Brief. https://druglandscape.com/ci/duobrii. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: